DAYBUE net sales projected to reach approx US$700m in 2028
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- FDA approves DAYBUE STIX (trofinetide), powder formulation
- Record DAYBUE net sales of US$101.1 million in Q3 2025
- Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
- Half Yearly Report and Accounts
- First site initiated for Neuren's PMS Phase 3 trial
Later from Neuren Pharmaceuticals
- Response to ASX Aware Letter
- Acadia provides update on EU regulatory submission
- Trading Halt
- Neuren receives US FDA meeting feeback for HIE and PTHS
- First patient dosed in Neuren PMS Phase 3 trial
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals